Federal Register #Docket No. DEA-1704

DEA Notice: Application by Royal Emerald Pharmaceuticals to Import Controlled Substances

This notice concerns the Drug Enforcement Administration's (DEA) review of Royal Emerald Pharmaceuticals' application to import controlled substances for research and manufacturing purposes. - Government Buyer: - Drug Enforcement Administration (DEA), Department of Justice - OEM/Vendor: - Royal Emerald Pharmaceuticals - Products/Controlled Substances Requested: - Marihuana Extract (Schedule I, drug code 7350) - Marihuana (Schedule I, drug code 7360) - Tetrahydrocannabinols (Schedule I, drug code 7370) - All substances to be imported as immature plants for use as raw materials in further cultivation and development of botanical raw materials or Active Pharmaceutical Ingredients (APIs) - Unique/Notable Requirements: - Importation is strictly for DEA-approved legitimate medical, scientific, research, and industrial purposes - No authorization for importing finished dosage forms for commercial sale - Registration does not permit activities beyond those specified for these drug codes - Public comments and hearing requests are being accepted regarding this application - Place of Performance/Delivery: - Royal Emerald Pharmaceuticals, Desert Hot Springs, CA

Description

Royal Emerald Pharmaceuticals has applied to be registered as an importer of basic classes of controlled substances, specifically Marihuana Extract, Marihuana, and Tetrahydrocannabinols, all Schedule I substances. The company plans to import immature plants as starting raw materials for cultivation under their Bulk Manufacturing registration, for legitimate medical, scientific, research, and industrial purposes approved by the Drug Enforcement Administration. Comments and objections to the application can be submitted electronically or in writing by May 18, 2026, and interested parties may request a hearing by the same date.

View original listing